The Schlondorff Laboratory is interested in the molecular mechanisms contributing to the progression of kidney diseases. This includes the contribution of Danger Associate Molecular Pattern (DAMP) molecules and their interaction with toll-like receptors (TLRs) to the sterile inflammation of chronic renal diseases in terms of the generation of pro-inflammatory cytokines, chemokines and the recruitment of specific types of leukocytes and especially macrophages and dendritic cells.
A combined in vitro-in vivo approach is employed including cell culture experiments, and in vivo mouse models of progressive renal diseases. In a translational approach, the genes identified as of interest in these experiments are examined in kidney biopsies from patients with a variety of renal diseases. This approach has already contributed to the identification of a number of novel pathways involved in progression of e.g. diabetic renal disease, progressive nephrosclerosis, lupus nephritis and chronic transplant nephropathy.
Lately the lab has identified BAMBI (BMP and Activin Membrane Bound Inhibitor), considered a modulator of the TGFβ family proteins, as a specifically endothelial cell expressed protein. BAMBI may influence angiogenesis and as such the progression of renal diseases due to endothelial damage and loss of endothelial cells from the renal microvasculature.
We are presently examining the potential contribution of BAMBI to progressive renal diseases using BAMBI knockout mice in models of renal disease affecting the microvasculature.
Detlef Schlondorff MD
1468 Madison Avenue
New York NY 10029